Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Isis, Alnylam in microRNA deal with Max Planck Society

Executive Summary

The Max Planck Society has co-exclusively licensed Isis Pharmaceuticals and Alnylam Pharmaceuticals (develops therapeutics based on RNA interference, RNAi) rights to RNAi patent applications related to the more than 100 mammalian microRNAs discovered by Alnylam co-founder Thomas Tuschl.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Alliance
    • R&D and Marketing (Licensing)

Related Companies